Mostrando 10 resultados de: 19
Filtros aplicados
Publisher
Pharmacogenomics Journal(6)
Pharmacogenomics(4)
Expert Opinion on Drug Metabolism and Toxicology(2)
Clinical Pharmacology and Therapeutics(1)
Current Pharmacogenomics and Personalized Medicine(1)
Área temáticas
Farmacología y terapéutica(13)
Enfermedades(6)
Fisiología humana(5)
Genética y evolución(2)
Medicina y salud(2)
CYP2C9 allele frequency differences between populations of Mexican-Mestizo, Mexican-Tepehuano, and Spaniards
ArticleAbstract: Earlier we had found that the CYP2C9*2 allelic frequency was lower in Mexican-Americans living in CaPalabras claves:CYP2C9, Hispanics, Mexican-Americans, Mexican-Mestizos, Mexican-Tepehuanos, pharmacogeneticsAutores:Adrián LLerena, Alanis-Bãuelos R.E., Dorado P., LARES, Licinio J., Penãs-Lledó E.M., Sosa-Macías M.G., Wong M.L.Fuentes:scopusCYP2C9, CYP2C19, ABCB1 genetic polymorphisms and phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy
ArticleAbstract: We aimed to explore the possible influence of CYP2C9 (∗2, ∗3 and IVS8-109 A>T), CYP2C19 (∗2, ∗3 andPalabras claves:Autores:Adrián LLerena, Dorado P., Familiar-López I., Fricke-Galindo I., Jung-Cook H., López-López M., Martínez-Juárez I.E., Monroy-Jaramillo N., Ortega-Vázquez A., Penãs-Lledó E.M.Fuentes:scopusCYP2D6 genetic polymorphisms in Southern Mexican Mayan Lacandones and Mestizos from Chiapas
ArticleAbstract: Aim: In previous CYP2D6 genotyping studies in Mexican-Amerindians a very low frequency of poor metabPalabras claves:CYP2D6, Lacandones, Mexican-Mestizo, pharmacogeneticsAutores:Adrián LLerena, Alonso E., Dorado P., López-López M., Ochoa-Morales A., Ortega A., Penãs-Lledó E.M., Vázquez T.C., Yescas-Gómez P.Fuentes:scopusCYP2D6 genotype and debrisoquine hydroxylation phenotype in Cubans and Nicaraguans
ArticleAbstract: CYP2D6 genotype and debrisoquine metabolic ratio (MR) were analyzed in 133 Nicaraguan Mestizos (NMs)Palabras claves:Cubans, CYP2D6, debrisoquine hydroxylation, Latinos, Nicaraguans, PhenotypeAutores:Adrián LLerena, Alvárez M., Calzadilla L.R., Dorado P., González I., Penãs-Lledó E.M., Pérez B., Ramirez R.Fuentes:scopusCYP2D6-1584C>G promoter polymorphism and debrisoquine ultrarapid hydroxylation in healthy volunteers
ArticleAbstract: Background & aim: The CYP2D6-1584C>G polymorphism (rs1080985) has been identified as a major factorPalabras claves:1584C>G, CYP2D6, debrisoquine, Healthy volunteers, ultrarapid metabolismAutores:Adrián LLerena, Alvárez M., Calzadilla L.R., Dorado P., González I., Naranjo M.E.G., Penãs-Lledó E.M., Pérez B., Ramirez R.Fuentes:scopusAripiprazole-induced parkinsonism and its association with dopamine and serotonin receptor polymorphisms
OtherAbstract:Palabras claves:Autores:Adrián LLerena, Dorado P., López-Torres E., Penãs-Lledó E.M., Salomón J., Vicario F.Fuentes:scopusEating disorder symptoms and CYP2D6 variation in cuban healthy females: A report from the Ibero-American network of pharmacogenetics
ArticleAbstract: CYP2D6 is involved in the metabolism of antidepressants drugs and of the endogenous neurotransmitterPalabras claves:Cuban population, CYP2D6, Eating disorder symptoms, Global pharmacogenetics, Healthy females, Public health pharmacogenetics, Ultrarapid metabolizersAutores:Adrián LLerena, Alvárez M., Calzadilla L.R., Dorado P., González I., Naranjo M.E.G., Penãs-Lledó E.M., Pérez B.Fuentes:scopusEffect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions
ArticleAbstract: Objectives: CYP2D6 drug-metabolising enzyme has been shown to be involved in fluoxetine metabolism iPalabras claves:CYP2C9, CYP2D6, Selective serotonin reuptake inhibitorsAutores:Adrián LLerena, Berecz R., Dorado P., González A.P., Penãs-Lledó E.M.Fuentes:scopusGenomic Ancestry, CYP2D6, CYP2C9, and CYP2C19 Among Latin Americans
ArticleAbstract: We present the distribution of CYP2D6, CYP2C9, and CYP2C19 variants and predicted phenotypes in 33 nPalabras claves:Autores:Adrián LLerena, Alvárez M., Barrantes R., Borbón-Orejuela A., Calzadilla L.R., Céspedes-Garro C., Cobaleda J., de Andrés F., Delgado R., Dorado P., Enrique Terán, Estévez-Carrizo F.E., Ferreiro V., Francisco J.López Hernández, Fricke-Galindo I., Galaviz-Hernandez C., Garza-Ocañas L., Gilman R.H., Grazina M., Humberto Fariñas, Jiménez-Arce G., Jung-Cook H., Lares-Aseff I., Lazalde-Ramos B.P., López-López M., Michelin L.A., Monroy-Jaramillo N., Moya G.E., Naranjo M.E.G., Ortega-Vázquez A., Ortiz-López R., Penãs-Lledó E.M., Pérez B., Pérez-Páramo Y.X., Ramírez-Roa R., Remírez D., Rodeiro I., Rodrigues-Soares F., Rojas-Martinez A., Santiago Terán, Sarmiento A.P., Scliar M.O., Sosa-Macías M.G., Tarazona-Santos E.M., Tinoco C.A., Zamudio R.Fuentes:googlescopusInterethnic differences in UGT1A4 genetic polymorphisms between Mexican Mestizo and Spanish populations
ArticleAbstract: UDP-glucuronosyltransferase 1A4 (UGT1A4) is a phase II drug-metabolizing enzyme that catalyzes the gPalabras claves:Glucuronidation, Interethnic differences, Mexican-Mestizo, Spaniards, UGT1A4Autores:Adrián LLerena, Alonso M.E., Cobaleda J., Dorado P., Gallego-Aguilera A., López M.L., MELANIE BRIGETTE ARROYO LOPEZ, Monroy-Jaramillo N., Ortega A., Penãs-Lledó E.M., Silva-Zolezzi I.Fuentes:googlescopus